Trillium (TRIL) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

As of late, it has definitely been a great time to be an investor in Trillium Therapeutics Inc. (TRIL).

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 35,731,818 common shares (the “Common Shares”) of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares (the “Series II First Preferred Shares”) of the Company (the “Offering”). The Common Shares are being sold at a public offering price of US$2.75 per Common Share and the Series II First Preferred Shares are being sold at a public offering price of US$2.75 per Series II First Preferred Share. In connection with the Offering, Trillium has granted the underwriters a 30-day option to purchase up to an additional 5,547,272 Common Shares.

When Jan Skvarka joined Cambridge’s Trillium Therapeutics as CEO in September 2019, the company had a paltry market cap of $27 million and had been stuck in a drug development rut. Months later, the company may be bouncing back.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of Directors, and Dr. Ali Behbahani has been appointed as a Board Observer, effective February 6, 2020.

CAMBRIDGE, Mass., March 10, 2020 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2020. On January 7, Trillium provided a data update on the ongoing dose escalation studies.

CAMBRIDGE, Mass., Feb. 28, 2020 -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the “Company”) (NASDAQ/TSX:.

Small-cap biotechs focused on virus treatments and cures have soared in recent weeks, but most folks should avoid these risky stocks.

Is (TRIL) Outperforming Other Medical Stocks This Year?

First patients in the 1.4 mg/kg cohort of TTI-621 and the 8.0 mg/kg cohort of TTI-622 clinical studies have been dosed. Sufficient drug supply inventory in place to complete ongoing studies. Currently no disruptions to drug supply chain expected, though risks are elevated.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has established an at-the-market equity program (the “ATM Program”). In connection with the ATM Program, the Company entered into a sales agreement (the “Sales Agreement”) with Evercore Group L.L.C. (the “Agent”) pursuant to which the Company may sell, through the Agent, acting as agent and/or principal, such number of common shares of the Company (“Common Shares”) as would result in aggregate gross proceeds to the Company of up to $50 million.

January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the Company has regained compliance with the Nasdaq Capital Market minimum bid price requirement, and the matter is now closed. According to the letter received from the Nasdaq Listing Qualifications Department, the closing bid price of the Company’s common stock has been at $1.00 per share or greater for a minimum of 10 consecutive days, and the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 41,279,090 common shares of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares of the Company (the “Offering”). The common shares and preferred shares were sold at a public offering price of US$2.75 per share. The number of shares sold includes the full exercise by the underwriters of their option to purchase up to an additional 5,547,272 common shares.

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

CAMBRIDGE, Mass., May 13, 2020 -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative.

Despite the lagging markets, companies that offer pharmaceuticals and FMCG products have witnessed a surge in recent weeks, largely driven by strong demand for their goods.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of common shares (the “Common Shares”) of the Company and Series II Non-Voting Convertible First Preferred Shares (the “Series II First Preferred Shares”) of the Company (the “Offering”). In addition, Trillium intends to grant the underwriters a 30-day option to purchase up to an additional amount of Common Shares equal to 15% of the Common Shares and Series II First Preferred Shares offered in the Offering.